Not Disclosed Neurodegeneration by Eli Lilly and Co for Neurodegenerative Diseases: Likelihood of Approval

Not Disclosed Neurodegeneration is under clinical development by Eli Lilly and Co and currently in Phase I for Neurodegenerative Diseases.

Extending FDA-approved cancer drug indications requires high patient numbers, study finds

Number of patient participants needed for secondary approval of a new cancer drug.

September 29, 2023

Study reveals distinct molecular features of proximal and distal colon cancers

The colon is often thought of as one organ, but the right and left parts of the colon have different molecular features in cancers.

February 27, 2024

Centene eliminates brokers’ commissions for Medicare drug plans

Health insurer Centene will not pay any commissions to brokers and agents who help people sign up for next year’s Medicare prescription drug plans. “We

August 27, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.